BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gupta V, Davancaze T, Good J, Kalia N, Anderson M, Wallin JJ, Brady A, Song A, Xu W. Bioanalytical qualification of clinical biomarker assays in plasma using a novel multi-analyte Simple Plex platform. Bioanalysis 2016;8:2415-28. [DOI: 10.4155/bio-2016-0196] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Frelau A, Pracht M, Le Sourd S, Lespagnol A, Corre R, Ménard C, Tarte K, Mosser J, Edeline J. Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns. Bulletin du Cancer 2018;105:S80-91. [DOI: 10.1016/s0007-4551(18)30393-x] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Arnold ME, Neubert H, Stevenson LF. The breadth of biomarkers and their assays: part 2. Bioanalysis 2016;8:2381-2. [PMID: 27855504 DOI: 10.4155/bio-2016-4984] [Reference Citation Analysis]
3 Fischer SK, Williams K, Wang L, Capio E, Briman M. Development of an IL-6 point-of-care assay: utility for real-time monitoring and management of cytokine release syndrome and sepsis. Bioanalysis 2019;11:1777-85. [PMID: 31547696 DOI: 10.4155/bio-2019-0192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
4 Dysinger M, Marusov G, Fraser S. Quantitative analysis of four protein biomarkers: An automated microfluidic cartridge-based method and its comparison to colorimetric ELISA. Journal of Immunological Methods 2017;451:1-10. [DOI: 10.1016/j.jim.2017.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
5 Gupta V, Kalia N, Yadav M, Noyes A, Good J, Hendricks R, Xu W. Optimization and qualification of the single molecule array digital immunoassay for IL-12p70 in plasma of cancer patients. Bioanalysis 2018;10:1413-25. [DOI: 10.4155/bio-2018-0083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecol Oncol 2018;149:585-91. [PMID: 29572027 DOI: 10.1016/j.ygyno.2018.03.050] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
7 Purushothama S, Dysinger M, Chen Y, Österlund K, Mora J, Chunyk AG, Peloquin R. Emerging technologies for biotherapeutic bioanalysis from a high-throughput and multiplexing perspective: insights from an AAPS emerging technology action program committee. Bioanalysis 2018;10:181-94. [DOI: 10.4155/bio-2017-0196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
8 Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE 3rd, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, Banchereau R, Leng N, Thastrom A, Shen X, Hashimoto K, Tayama D, van der Heijden MS, Rosenberg JE, McDermott DF, Powles T, Hegde PS, Huseni MA, Mariathasan S. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat Med 2020;26:693-8. [PMID: 32405063 DOI: 10.1038/s41591-020-0860-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 31.5] [Reference Citation Analysis]
9 Wessels U, Mackeben K, Stubenrauch K. Use of Ella ® to facilitate drug quantification and antidrug antibody detection in preclinical studies. Bioanalysis 2019;11:153-64. [DOI: 10.4155/bio-2018-0288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]